type public company nasdaq stockholm sobi industry pharmaceutical headquarters stockholm sweden products inflammation and genetic diseases with three late stage biological development projects within haemophilia and neonatology . the company also market a portfolio of specialty and rare disease products for partner companies in the areas of hematology oncology emergency medicines and antidotes and infectious diseases and specialty care . parent investor ab 40 % website sobi.com swedish orphan biovitrum ab publ sobi is an international specialty healthcare company dedicated to rare diseases based in stockholm sweden . contents 1 history 2 company 3 external links 4 references history edit sobi has been involved in the process development and manufacturing of recombinant protein drugs since the technology was first developed around 30 years ago then as part of kabivitrum . biovitrum was formed in 2001 through the merger of several units of pharmacia now pfizer and spun off to a consortium of investors led by nordic capital and mpm capital funds . operations included a research unit focused on metabolic diseases a process development unit for protein drugs and a plasma product operation . in 2002 sobi sold its plasma operation to octapharma as part of efforts to concentrate operations on protein based and small molecular drugs . in 2004 biovitrum started to manufacture the active protein component for wyeth s now pfizer s refacto and refacto xynta drugs for treatment of hemophilia and marketing of specialty pharmaceuticals refacto mimpara and kineret was initiated in the nordic region . in 2005 the research and development portfolio was expanded through the acquisition of arexis a swedish biotech company and the following year a partnership was formed with syntonix subsequently biogen idec to jointly develop a drug for hemophilia b a long lasting recombinant factor ix fc fusion protein candidate rfixfc . this partnership was extended the following year to also include the development of a long lasting recombinant factor viii fc fusion protein candidate rfviiifc for the treatment of hemophilia a. in 2008 an agreement with amgen regarding the acquisition of the products kepivance and stemgen as well as a global license for kineret was signed in 2009 sobi and partner biogen idec took the decision to enter final registration studies for the recombinant factor fixfc . the company also received positive data regarding its kiobrina phase ii program an investigational enzyme replacement therapy to improve growth in preterm infants who receive pasteurized breast milk or infant formula . in 2010 biovitrum acquired swedish orphan international holding ab a pioneer in orphan drugs and swedish orphan biovitrum ab publ was formed . 1 in addition the decisions to advance both hemophilia projects as well as kiobrina into phase iii were taken . the following year the first patient was enrolled in the phase 3 study for kiobrina and data from the rfviiifc hemophilia phase i ii study were presented showing an approximately 1.7 fold increase in half life compared with advate . the company also established a us subsidiary . in 2012 the supply agreement with pfizer for refacto xyntha was extended until 2020 in addition to the agreement to return the co promotion rights for the nordic region for refacto to pfizer for a payment of usd 47.4 m. the same year the sobi and partner biogen idec initiated global pediatric clinical trials of their long lasting hemophilia a and b product candidates . company edit sobi is an international specialty healthcare company dedicated to rare diseases . the company s mission is to develop and deliver innovative therapies and services to improve the lives of patients . the product portfolio is primarily focused on inflammation and genetic diseases with three late stage biological development projects within haemophilia and neonatology . the company also market a portfolio of specialty and rare disease products for partner companies . sobi is a pioneer in biotechnology with world class capabilities in protein biochemistry and biologics manufacturing . in 2013 sobi had total revenues of sek 2.2 billion 253 m and about 550 employees . the share sto sobi is listed on nasdaq omx stockholm . 2 external links edit sobi website sobi partner products website references edit change of company name for biovitrum ab 2010 06 21 sobi report for the fourth quarter and full year results 2013 2014 02 20 comment on biovitrum ipo 2006 09 04 retrieved from https en.wikipedia.org w index.php title swedish orphan biovitrum & oldid 743107269 categories pharmaceutical companies of swedencompanies related to the wallenberg family2001 establishments in swedencompanies established in 2001companies based in stockholmcompanies listed on the stockholm stock exchange navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages svenska edit links this page was last modified on 7 october 2016 at 21 28 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view